Related Experiment Video
Updated: May 26, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[DNMT3A gene mutations in acute myeloid leukemia]
1Department of Hematology, Xiamen University, Xiamen, Fujian Province, China.
Mutations in the DNMT3A gene are common in acute myeloid leukemia (AML), affecting DNA methylation and prognosis. Further research is needed to clarify their role in minimal residual disease and as therapeutic targets.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Epigenetic alterations, particularly abnormal DNA methylation, are crucial in cancer development.
- Mutations in DNA methyltransferase 3A (DNMT3A) have been identified in acute myeloid leukemia (AML), impacting DNA methylation patterns and patient prognosis.
Purpose of the Study:
- To review current understanding of DNMT3A gene mutations in AML.
- To discuss the potential role of DNMT3A mutations in leukemogenesis and their prognostic implications.
Main Methods:
- Review of existing literature on DNMT3A mutations in AML.
- Analysis of sequencing data identifying single nucleotide variations and mutation hotspots (e.g., Arg882).
Main Results:
- DNMT3A mutations occur in approximately 20% of AML patients.
- These mutations are associated with older age (>60), specific AML subtypes (M4/M5), and intermediate-risk cytogenetics.
- DNMT3A alterations are also observed in myelodysplastic syndrome (MDS) and primary myelofibrosis (PMF), suggesting an early role in leukemia development.
Conclusions:
- DNMT3A mutations are significant in AML pathogenesis and are linked to specific clinical and genetic features.
- The prognostic value of DNMT3A mutations concerning minimal residual disease and their potential as therapeutic targets require further investigation in large AML cohorts.
More Related Videos
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
10:33Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Published on: October 15, 2018
Related Concept Videos
Abnormal Proliferation
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...